AG10
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 28 | 全身性アミロイドーシス | 9 |
28. 全身性アミロイドーシス
臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
Showing 1 to 9 of 9 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04882735 (ClinicalTrials.gov) | September 202120210900 | 29/4/202120210429 | Efficacy and Safety of Acoramidis (AG10) in Subjects With Transthyretin Amyloid Polyneurophathy (ATTRibute-PN) Efficacy and Safety of Acoramidis (AG10) in Subjects With Transthyretin Amyloid Polyneurophathy (ATT ... | A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Acoramidis in Subjects With Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Study) A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Acoramid ... | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | Drug: Acoramidis | Eidos Therapeutics | NULL | Not yet recruiting | 18 Years | 90 Years | All | 100 | Phase 3 | NULL |
| 2 | EUCTR2018-004670-10-BG (EUCTR) | 25/11/202020201125 | 04/08/202020200804 | Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) Study of the Efficacy and Safety of AG10in participants with Transthyretin Amyloid Polyneuropathy (A ... | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) - Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10in S ... | Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) MedDRA version: 20.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) MedDRA version: 20.0;Level: LLT;Classific ... | Product Name: AG10 Product Code: AG10 HCl INN or Proposed INN: AG10 HCl Other descriptive name: 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID Product Name: AG10 Product Code: AG10HCl INN or Proposed INN: AG10HCl Other descriptive name: 3-(3-(3,5 ... | Eidos Therapeutics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 145 | Phase 3 | Portugal;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Bulgaria;Germany;Netherlands;New Zealand Portugal;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Brazil; ... | ||
| 3 | NCT04418024 (ClinicalTrials.gov) | October 21, 202020201021 | 22/5/202020200522 | Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Polyneurophathy | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10in S ... | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | Drug: AG10;Drug: Placebo | Eidos Therapeutics, a BridgeBio company | NULL | Withdrawn | 18 Years | 90 Years | All | 0 | Phase 3 | United States;Canada;Spain |
| 4 | EUCTR2018-004670-10-FR (EUCTR) | 29/09/202020200929 | 05/06/202020200605 | Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) Study of the Efficacy and Safety of AG10in participants with Transthyretin Amyloid Polyneuropathy (A ... | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) - Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10in S ... | Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) MedDRA version: 20.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) MedDRA version: 20.0;Level: LLT;Classific ... | Product Name: AG10 Product Code: AG10 HCl INN or Proposed INN: AG10 HCl Other descriptive name: 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID Product Name: AG10 Product Code: AG10HCl INN or Proposed INN: AG10HCl Other descriptive name: 3-(3-(3,5 ... | Eidos Therapeutics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 145 | Phase 3 | Portugal;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Bulgaria;Germany;Netherlands;New Zealand Portugal;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Brazil; ... | ||
| 5 | EUCTR2018-004670-10-DE (EUCTR) | 28/09/202020200928 | 25/05/202020200525 | Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) Study of the Efficacy and Safety of AG10in participants with Transthyretin Amyloid Polyneuropathy (A ... | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) - Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10in S ... | Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) MedDRA version: 20.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) MedDRA version: 20.0;Level: LLT;Classific ... | Product Name: AG10 Product Code: AG10 HCl INN or Proposed INN: AG10 HCl Other descriptive name: 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID Product Name: AG10 Product Code: AG10HCl INN or Proposed INN: AG10HCl Other descriptive name: 3-(3-(3,5 ... | Eidos Therapeutics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 145 | Phase 3 | Portugal;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Bulgaria;Germany;Netherlands;New Zealand Portugal;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Brazil; ... | ||
| 6 | EUCTR2018-004670-10-PT (EUCTR) | 31/08/202020200831 | 04/06/202020200604 | Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) Study of the Efficacy and Safety of AG10in participants with Transthyretin Amyloid Polyneuropathy (A ... | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) - Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10in S ... | Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) MedDRA version: 20.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) MedDRA version: 20.0;Level: LLT;Classific ... | Product Name: AG10 Product Code: AG10 HCl INN or Proposed INN: AG10 HCl Other descriptive name: 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID Product Name: AG10 Product Code: AG10HCl INN or Proposed INN: AG10HCl Other descriptive name: 3-(3-(3,5 ... | Eidos Therapeutics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 145 | Phase 3 | Portugal;New Zealand;Taiwan;Turkey;Russian Federation;Spain;Italy;France;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Bulgaria;Germany;Netherlands Portugal;New Zealand;Taiwan;Turkey;Russian Federation;Spain;Italy;France;Hungary;Mexico;Canada;Argen ... | ||
| 7 | EUCTR2018-004670-10-IT (EUCTR) | 24/07/202020200724 | 24/05/202120210524 | Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) Study of the Efficacy and Safety of AG10in participants with Transthyretin Amyloid Polyneuropathy (A ... | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) - Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10in S ... | Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) MedDRA version: 20.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) MedDRA version: 20.0;Level: LLT;Classific ... | Product Name: AG10 Product Code: [AG10 HCl] INN or Proposed INN: AG10 HCl Other descriptive name: 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID Product Name: AG10 Product Code: [AG10HCl] INN or Proposed INN: AG10HCl Other descriptive name: 3-(3-(3 ... | Eidos Therapeutics, Inc | NULL | Not Recruiting | Female: yes Male: yes | 145 | Phase 3 | Portugal;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Bulgaria;Germany;Netherlands;New Zealand Portugal;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Poland; ... | ||
| 8 | EUCTR2018-004670-10-HU (EUCTR) | 07/07/202020200707 | 12/05/202020200512 | Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) Study of the Efficacy and Safety of AG10in participants with Transthyretin Amyloid Polyneuropathy (A ... | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) - Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10in S ... | Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) MedDRA version: 20.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) MedDRA version: 20.0;Level: LLT;Classific ... | Product Name: AG10 Product Code: AG10 HCl INN or Proposed INN: AG10 HCl Other descriptive name: 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID Product Name: AG10 Product Code: AG10HCl INN or Proposed INN: AG10HCl Other descriptive name: 3-(3-(3,5 ... | Eidos Therapeutics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 145 | Phase 3 | Portugal;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Bulgaria;Germany;Netherlands;New Zealand Portugal;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Brazil; ... | ||
| 9 | EUCTR2018-004670-10-NL (EUCTR) | 00000000 | 03/02/202120210203 | Study of the Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) Study of the Efficacy and Safety of AG10in participants with Transthyretin Amyloid Polyneuropathy (A ... | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) - Efficacy and Safety of AG10 in participants with Transthyretin Amyloid Polyneuropathy (ATTR-PN) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10in S ... | Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) MedDRA version: 20.0;Level: LLT;Classification code 10057949;Term: Familial amyloid polyneuropathy;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) MedDRA version: 20.0;Level: LLT;Classific ... | Product Name: AG10 Product Code: AG10 HCl INN or Proposed INN: AG10 HCl Other descriptive name: 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID Product Name: AG10 Product Code: AG10HCl INN or Proposed INN: AG10HCl Other descriptive name: 3-(3-(3,5 ... | Eidos Therapeutics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 145 | Phase 3 | Portugal;Serbia;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Bulgaria;Netherlands;Germany;New Zealand Portugal;Serbia;Taiwan;Spain;Turkey;Russian Federation;Italy;France;Hungary;Mexico;Canada;Argentina; ... |